טוען...

Patterns of relapse and prognosis after bevacizumab failure in recurrent glioblastoma

BACKGROUND: Bevacizumab has recently been approved by the US Food and Drug Administration for recurrent glioblastoma (GBM). However, patterns of relapse, prognosis, and outcome of further therapy after bevacizumab failure have not been studied systematically. METHODS: We identified patients at Memor...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
Main Authors: Iwamoto, F M., Abrey, L E., Beal, K, Gutin, P H., Rosenblum, M K., Reuter, V E., DeAngelis, L M., Lassman, A B.
פורמט: Artigo
שפה:Inglês
יצא לאור: American Academy of Neurology 2009
נושאים:
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC2839807/
https://ncbi.nlm.nih.gov/pubmed/19822869
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1212/WNL.0b013e3181bc0184
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!